ClearPoint Neuro, Inc.
- Open
- 14.33
- Day high
- 14.76
- Day low
- 13.86
- Prev close
- 14.31
- Volume
- 343K
- Mkt cap
- $434M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 40.3
- P/S
- 10.3
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.5M over the last 3 months (0 open-market buys, 3 sales)
- 🏛Institutions accumulating (13F)
ClearPoint Neuro, Inc. (CLPT) is a Healthcare company listed on NASDAQ. The stock is up 43% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4). Drillr has 2 published research articles covering CLPT.
ClearPoint Neuro, Inc. (CLPT) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CLPT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 3, 2026 | $-0.29 | $-0.38 | -32.6% | $11M | -14.6% |
| May 13, 2026 | $-0.28 | $-0.32 | -14.3% | $12M | +1.3% |
| Mar 17, 2026 | $-0.20 | $-0.27 | -37.5% | $10M | +3.6% |
| Nov 6, 2025 | $-0.20 | $-0.21 | -5.0% | $9M | -14.8% |
| Feb 26, 2025 | $-0.15 | $-0.20 | -33.3% | $8M | -5.6% |
| Nov 7, 2024 | $-0.17 | $-0.18 | -5.9% | $8M | +4.4% |
| Mar 12, 2024 | $-0.22 | $-0.19 | +13.6% | $7M | +4.3% |
| Nov 9, 2023 | $-0.25 | $-0.20 | +20.0% | $6M | -9.3% |
| May 11, 2023 | $-0.18 | $-0.23 | -27.8% | $5M | +6.5% |
| Mar 1, 2023 | $-0.22 | $-0.18 | +18.2% | $5M | -0.5% |
| Aug 9, 2022 | $-0.18 | $-0.18 | +0.0% | $5M | +2.3% |
| Mar 1, 2022 | $-0.19 | $-0.19 | +0.0% | $4M | -0.4% |
CLPT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 6, 2026 | FLETCHER R JOHNdirector | Grant | 662 | $17.84 |
| Jul 6, 2026 | Richards Timothy T.director | Grant | 222 | $17.84 |
| Jul 2, 2026 | STIGALL L. JEREMYofficer: Chief Business Officer | Grant | 1,781 | $11.93 |
| Jul 2, 2026 | D'Alessandro Daniloofficer: Chief Financial Officer | Grant | 1,085 | $11.93 |
| Jul 2, 2026 | BURNETT JOSEPHdirector, officer: CEO and President | Grant | 1,361 | $11.93 |
| Jul 1, 2026 | BURNETT JOSEPHdirector, officer: CEO and President | Sell | 20,000 | $19.38 |
| Jul 1, 2026 | BURNETT JOSEPHdirector, officer: CEO and President | Option | 20,000 | $2.50 |
| Jun 22, 2026 | BURNETT JOSEPHdirector, officer: CEO and President | Sell | 1,843 | $17.94 |
| Jun 22, 2026 | BURNETT JOSEPHdirector, officer: CEO and President | Sell | 60,000 | $17.79 |
| Jun 22, 2026 | BURNETT JOSEPHdirector, officer: CEO and President | Option | 60,000 | $2.50 |
| Jun 8, 2026 | Richards Timothy T.director | Tax | 376 | $13.30 |
| Jun 8, 2026 | Richards Timothy T.director | Option | 500 | $10.00 |
| Jun 2, 2026 | Richards Timothy T.director | Sell | 5,415 | $12.17 |
| May 26, 2026 | Klein Matthew B.director | Grant | 12,820 | — |
| May 26, 2026 | JOHNSON B KRISTINEdirector | Grant | 12,820 | — |
Source: CLPT SEC Form 4 filings, latest Jul 6, 2026. For informational purposes only — not investment advice.
See the full CLPT insider & 13F page →CLPT research & analysis
Rare-Disease Gene Therapy Shifts From Sham-Surgery Control to Delivery Hardware and Endpoint Instruments
The FDA told uniQure a sham-surgery control is no longer required, moving the cost of rare-disease gene therapy onto delivery hardware and endpoint instruments.
BCDABIIBDNLIRare CNS Gene Therapy Moves Past Sham-Surgery Control
uniQure, ClearPoint and BioCardia disclosed the FDA no longer requires a sham-surgery control in rare CNS gene therapy, moving the gate to delivery hardware.
BCDACYRXMGTX
ClearPoint Neuro, Inc. company profile
Overview
ClearPoint Neuro, Inc. (NASDAQ:CLPT) is a medical device company founded in 1998 and headquartered in Solana Beach, California. Originally incorporated as MRI Interventions, Inc., the company changed its name to ClearPoint Neuro in February 2020 to better reflect its focus on neurological applications. The company specializes in developing and commercializing platforms that enable minimally invasive surgical procedures in the brain under direct, real-time magnetic resonance imaging (MRI) guidance. ClearPoint has established itself as a key enabler in the emerging cell and gene therapy market while also serving traditional neurosurgery applications.
Business
ClearPoint Neuro operates in the medical device industry, specifically focusing on image-guided neurosurgery and drug delivery systems. The company's core technology enables surgeons to perform brain procedures with unprecedented precision by using real-time MRI imaging to guide instruments directly to target locations within the brain. The company operates through three main business segments: Biologics and Drug Delivery (55% of revenue): This segment provides specialized cannulas, navigation services, and preclinical testing for pharmaceutical companies developing cell and gene therapies for neurological diseases. The SmartFlow cannula is a key product that allows precise delivery of therapeutic agents directly into specific brain regions. This segment has become increasingly important as more gene therapies for brain disorders advance through clinical trials. Neurosurgery Navigation and Therapy (33% of revenue): This segment focuses on traditional neurosurgical procedures, particularly deep brain stimulation (DBS) for conditions like Parkinson's disease, essential tremor, and depression. The ClearPoint Navigation System allows surgeons to place electrodes with millimeter precision while the patient is inside an MRI scanner. The company is expanding this capability to operating room environments with its SmartFrame OR system. Capital Equipment and Software (12% of revenue): This segment includes sales and leases of the ClearPoint hardware systems, software licenses, and related accessories. The ClearPoint 3.0 software represents the latest generation of navigation technology, enabling both MRI-guided and CT-guided procedures. The underlying technology addresses a fundamental challenge in neurosurgery: how to accurately target specific locations in the brain while minimizing damage to healthy tissue. Traditional neurosurgery relies on pre-operative imaging, but the brain can shift during surgery. ClearPoint's real-time MRI guidance allows surgeons to see exactly where their instruments are positioned throughout the procedure.
Revenue model
ClearPoint Neuro generates revenue through multiple complementary business models tailored to different customer segments and use cases. Product Sales represent the largest revenue stream, primarily from selling specialized cannulas and disposable accessories to pharmaceutical companies conducting clinical trials. The company charges per procedure, with pricing typically ranging from thousands to tens of thousands of dollars depending on the complexity and type of therapy being delivered. Service Fees come from providing navigation services, preclinical testing, and clinical support to biopharma partners. The company operates specialized facilities where pharmaceutical companies can conduct Good Laboratory Practice (GLP) studies required for regulatory approval. These services command premium pricing due to the specialized expertise required. Equipment Sales and Leases generate revenue from hospitals and research institutions purchasing or leasing ClearPoint navigation systems. The company has shifted toward rental and lease programs to reduce the capital burden on customers while creating recurring revenue streams. Licensing and Royalties provide ongoing revenue from strategic partnerships. For example, the company receives royalties from approved therapies that use its co-labeled SmartFlow cannula, creating long-term revenue potential as gene therapies reach commercial markets. Several factors influence the company's margins and profitability. Positive margin drivers include the high-value nature of brain procedures, which justifies premium pricing; economies of scale as production volumes increase; and the recurring nature of disposable products for each procedure. The company's gross margins have improved from 53% to over 60% as the business has scaled. Margin pressures come from the need for continuous R&D investment to stay ahead of competitors; regulatory compliance costs for medical devices; the capital-intensive nature of establishing GLP facilities; and the currently small scale of the gene therapy market, which limits volume efficiencies. Additionally, the company faces reimbursement challenges as many procedures are still considered experimental by insurance providers.
Risks & safety
ClearPoint Neuro presents a moderate margin of safety with strong liquidity but ongoing profitability challenges. Liquidity and Solvency: • Cash position: $12.4 million as of Q1 2025, down from $20.1 million at year-end 2024 • Current ratio: 3.53x indicating strong short-term liquidity • Debt-to-equity ratio: 0.17, representing minimal debt burden • Free cash flow: -$6.4 million in Q1 2025, indicating continued cash burn • Recent $32 million funding from Oberland Capital provides additional runway Operational Metrics: • Revenue growth: 31% in 2024, maintaining strong top-line momentum • Gross margins: 60%+ and improving, indicating pricing power • Operating leverage: Revenue growing faster than expenses • Cash burn rate: Approximately $6-7 million per quarter at current levels Valuation Considerations: • Price-to-book ratio: 16.5x, indicating high valuation relative to tangible assets • Enterprise value to EBITDA: Negative due to current losses • Graham net-net ratio: 0.30, suggesting limited downside protection from liquidation value • Market cap relative to revenue run rate suggests growth expectations are high Other Risk Factors: • Pre-profitability company dependent on continued funding • Regulatory risks in medical device industry • Concentration risk with pharmaceutical partner dependencies • Small scale relative to potential large-cap competitors
Recent development
Over the past few years, ClearPoint Neuro has undergone significant strategic evolution, transitioning from a traditional neurosurgery navigation company to a key enabler of the emerging cell and gene therapy market. The company launched its "Fast Forward" strategic phase in 2024, focusing on three core pillars: extending its lead in cell and gene therapy delivery, evolving its product portfolio for simpler workflows, and expanding its global installed base. Product Innovation and Regulatory Achievements: The company achieved a major milestone with the FDA approval of PTC Therapeutics' Upstaza gene therapy, which uses ClearPoint's co-labeled SmartFlow cannula - marking the first approved gene therapy utilizing the company's technology. Building on this success, ClearPoint submitted a 510(k) application for its SmartFlow cannula specifically for REGENXBIO's gene therapy program and launched its ClearPoint 3.0 navigation software, which enables procedures in traditional operating rooms rather than requiring MRI suites. Market Expansion and Partnerships: The company has dramatically expanded its pharmaceutical partnerships from around 50 to over 60 active biopharma partners, with seven partnered programs designated for FDA accelerated pathways. ClearPoint activated 19 new customer sites in 2024 and now operates more than 100 activated centers worldwide. The company is targeting 150-300 hospitals globally and expects 15-20 new site activations in 2025. Operational Infrastructure Development: ClearPoint completed the transition to its new 20,000 square foot manufacturing facility in Carlsbad, California, and is preparing for GLP (Good Laboratory Practice) certification in the second half of 2025. This will enable the company to conduct preclinical studies required for regulatory approval, representing a significant expansion of its service capabilities. The company has also been aggressively hiring preclinical and field support teams to support anticipated growth in gene therapy approvals. Financial and Strategic Positioning: The company secured $32 million in funding from Oberland Capital, providing additional runway for growth investments. ClearPoint has also implemented new business models, including the Pathfinder subscription program and various partnership structures ranging from co-development agreements to milestone payments and royalty arrangements, creating multiple revenue streams from its pharmaceutical partnerships.
CLPT company profile · for informational purposes only — not investment advice.
Track CLPT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free